Nitrosamines Impurities Remediation

Nitrosamines Impurities Risk Assessment & Remediation

N

itrosamines are produced in the reaction of nitrites and secondary amines. In 2018, angiotensin II receptor blockers (ARB) medicines were withdrawn from the market in the US due to the presence of an impurity, N-nitrosodimethylamine (NDMA). Since then, regulatory agencies and pharmaceutical companies around the world have an increased focus on the potential for nitrosamine impurity growth in marketed drug products.

In 2021, FDA released its guidance document “Control of Nitrosamine Impurities in Human Drugs” to help companies reduce the levels of nitrosamine impurities in their drug products and ultimately achieve compliance to tightening US and global standards. Solving nitrosamine impurity challenges requires a multidisciplinary approach understanding API manufacturing technology, analytical chemistry, toxicology, formulation technology, and manufacturing processes technology. As a multidisciplinary, end-to-end R&D service company, Vici Health Sciences is well positioned to solve your nitrosamine impurity problems both during development and post-commercialization. 

At Vici Health Sciences, we help you with:

We help companies handle and manage nitrosamine-related projects and meet Agency mandated deadlines. Contact us to discuss your options for nitrosamine-related impurities.